Latest Quarterly Update News

BluGlass Limited reports a robust project pipeline exceeding US$100 million, bolstered by initial orders from Collins Aerospace and Infleqtion Inc, alongside strategic board appointments and a $6 million R&D tax rebate.

Petratherm Limited has significantly extended high-grade titanium mineralisation at its Rosewood East prospect and discovered a new Echo Prospect, advancing its Muckanippie Project towards a maiden resource.

JB Hi-Fi reports solid Q1 FY26 sales growth, led by a remarkable 39.3% increase in New Zealand, while Australian sales maintain steady momentum. The Good Guys and e&s show modest gains as the group prepares for a critical Q2.

MinRex Resources reports promising rare earth element and titanium dioxide results from its maiden drilling at the Fraser Range Project, while extending its option to acquire a 50% stake until January 2026.

Gathid Ltd reports a stable customer base despite a short-term dip in annual recurring revenue, while managing ongoing legal disputes and positioning for renewed growth.

FlexiRoam Limited has reported its strongest quarterly operating cash flow ever, signalling a successful business reset and setting the stage for growth with a new AI-assisted connectivity platform.

CuFe Ltd has announced a dramatic 400% increase in contained copper at its Gecko project, alongside an upgraded Orlando resource and a $5.4 million capital raise to advance its Tennant Creek development plans.

L1 Group has completed its merger with Platinum Asset Management, forming a $16.9 billion investment powerhouse focused on stabilising funds under management and unlocking significant cost synergies.

Odyssey Gold Limited has reported significant progress on its Tuckanarra Gold Project, including a positive Mining Technical Study, robust drilling results, and a $4 million capital raise to fund ongoing exploration and development.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Klevo Rewards Limited reports a strong quarter with a tenfold increase in customer receipts and positive cash flow, completing a $3.4 million entitlement offer and advancing steps toward ASX reinstatement.